Anti-tumor activities and immunomodulatory effects of BMS-202 is studied using in vitro (human CD3+ cells) and in vivo studies; BMS-202, PD-1/PD-L1 binding is blocked leading to increased IFN-γ secretion in vitro (36). The gene discussed is CD274; the disease is neoplasm.